Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Khalifa

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2017
Interobserver variability in the delineation of the primary lung cancer and lymph nodes on different four-dimensional computed tomography reconstructionsSusan Mercieca, José S A Belderbos, Katrien De Jaeger, et al.
Cancers|June 29, 2019
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score AnalysisStéphanie Servagi Vernat, Jonathan Khalifa, Xu-Shan Sun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 11, 2025
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30)Paul Sargos, Géraldine Pignot, Carine Bellera, et al.
Acta Oncologica (Stockholm, Sweden)|July 5, 2019
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancerRudi Apolle, Steffen Appold, Henk P Bijl, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 12, 2025
Radiotherapy for lung metastasesAntonin Levy, Marion Tonneau, Julien Darréon, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 29, 2025
Reirradiation of lung, breast and bone tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologiqueYuedan Zhou, Alexandre Escande, Arnaud Beddok, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 13, 2023
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy groupKanta Ka, Renaud Schiappa, Mario Terlizzi, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 28, 2025
Radiotherapy for primary lung cancer: 2025 updateJonathan Khalifa, Yasmine El Houat, Sébastien Thureau, et al.
Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2017
Interobserver variability in the delineation of the primary lung cancer and lymph nodes on different four-dimensional computed tomography reconstructionsSusan Mercieca, José S A Belderbos, Katrien De Jaeger, et al.
Cancers|June 29, 2019
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score AnalysisStéphanie Servagi Vernat, Jonathan Khalifa, Xu-Shan Sun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 11, 2025
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30)Paul Sargos, Géraldine Pignot, Carine Bellera, et al.
Acta Oncologica (Stockholm, Sweden)|July 5, 2019
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancerRudi Apolle, Steffen Appold, Henk P Bijl, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 12, 2025
Radiotherapy for lung metastasesAntonin Levy, Marion Tonneau, Julien Darréon, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 29, 2025
Reirradiation of lung, breast and bone tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologiqueYuedan Zhou, Alexandre Escande, Arnaud Beddok, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 13, 2023
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy groupKanta Ka, Renaud Schiappa, Mario Terlizzi, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 28, 2025
Radiotherapy for primary lung cancer: 2025 updateJonathan Khalifa, Yasmine El Houat, Sébastien Thureau, et al.
Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.
Pageof 6